Immunotherapy: Advances and Updates

November 4, 2016

Learning Objectives

  • Manage the treatment plan for patients treated with immunotherapeutic agents, factoring in the concept of pseudo-progression
  • Counsel patients on the necessity of PD-L1 biomarker testing in advance of initiating immunotherapy regimens
  • Summarize the role of PD-L1 in patients set to receive immunotherapeutic regimens for melanoma
Course summary
Available credit: 
  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC
Course opens: 
11/04/2016
Course expires: 
06/08/2017
Event starts: 
11/04/2016 - 11:30am
Event ends: 
11/04/2016 - 12:30pm
Cost:
$0.00
Parent activity set: 
Rating: 
0
Gaylord National Hotel
National Harbor, MD
United States

Available Credit

  • 1.00 ACPE
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Attendance
  • 1.00 ANCC

Price

Cost:
$0.00
Please login or register to take this course.